Category Archives: Gene Therapy Clinics

Twist Bioscience to Join Proteona in Global Alliance to Protect Immunocompromised Patients From COVID-19 Infection – BioSpace

By adminJune 2, 2020Gene Therapy Clinics

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Proteona today announced that Twist BioscienceCorporation (Nasdaq: TWST) will join the international alliance led by Proteona to develop neutralizing antibody therapy against COVID-19 for vulnerable immunocompromised patients. Utilizing the highly parallel silicon-based DNA synthesis platform, Twist has the ability to manufacture millions of oligos of different lengths with industry leading accuracy. This core capability enables Twist Biopharma, a division of Twist Bioscience, to identify numerous neutralizing antibody sequences and use in house capability to generate and optimize IgG antibodies ready for analysis.

The international alliance was initiated by Proteona in response to the urgent need of patients most at risk facing the pandemic, such as those with blood cancers. Due to preexisting conditions, these patients have a higher risk of complications from infections. They may not respond well to vaccination once available because of their compromised immune system. The alliance aims to develop antibody therapies to provide a safe and targeted treatment for these vulnerable populations.

Twist Bioscience is an instrumental addition to the alliance, said Andreas Schmidt, CEO of Proteona. Their expertise in biologics development is the perfect complement to our group. With Twist onboard, we complete the cycle of antibody development from sample to the clinics.

Proteona, who is leading the alliance, continues to conduct screening for potential candidate antibodies. Using its single cell proteogenomics technology which enables the simultaneous screening of antibodies targeting multiple viral variants, Proteona is analyzing blood samples from recovered COVID-19 patients, and screening for B cells that produce neutralizing antibodies against the SARS-CoV-2 virus. 10x Genomics and NovogeneAIT are providing enabling technologies for single cell analysis and sequencing respectively. The clinical partners at the Heidelberg University Hospital, the German Cancer Research Center, and the Natural and Medical Sciences Institute (NMI) at the University of Tbingen are assisting in sample collection and coordination, and provide first-hand clinical insight. Twist will synthesize and express the antibody sequences as functional antibodies, which can then be tested by collaborators in animal and cell studies for safety and efficacy.

We are pleased to partner with biotechnology leaders in the field of COVID-19 research including Proteona, 10x Genomics, NovogeneAIT, as well as the exceptional clinical research centers, said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. Finding viable antibody therapeutics to effectively treat COVID-19 will require massive cross-border collaborations like this alliance, amplifying each groups technology to be more than the sum of the individual organizations.

The pipeline resulting from this alliance has applications beyond infectious diseases, said Schmidt. Antibody therapy, thanks to its flexibility, scalability and low toxicity, are already helping patients with immune disorders and blood cancers. The need for improved antibody discovery platforms continues to increase. The same workflow can quickly be adapted and applied to other applications.

About Proteona

Proteona Pte. Ltd. is a biomedical company located in Singapore, Germany, and the US that is pioneering the use of single cell proteogenomics to improve clinical outcomes in cancer. Using a combination of innovative single cell assays and AI-assisted bioinformatics, Proteona provides a comprehensive sample to answer service that enables users to phenotype cells using standard protein markers and gain a deeper understanding of cell activity based upon their gene expression profiles. Proteona is a spin-off from the National University of Singapore (NUS) and the Agency for Science, Technology and Researchs (A*STAR). Proteona is leading an international alliance to develop neutralizing antibodies against coronaviruses including SARS-CoV-2. In addition, Proteona supports partners developing COVID-19 therapies and vaccines by providing single cell immune profiling services. https://proteona.com.

About Twist Biopharma

By leveraging our unique ability to manufacture DNA at scale, we can construct proprietary antibody libraries precisely designed to match sequences that occur in the human body. This library of libraries gives our partners an integral and unbiased resource for antibody therapeutic discovery and optimization. This precise and rational approach to library fabrication combined with sophisticated bioinformatics and software expertise expedites antibody discovery by decreasing risk, increasing speed, and lowering the failure rate for antibody therapeutic development.

About Twist Bioscience Corporation

Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by writing DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including diagnostics, therapeutics, industrial chemicals, agriculture and academic research. For more information visit http://www.twistbioscience.com and http://www.twistbiopharma.com.

Legal Notice Regarding Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Biosciences actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risk of breach of Twists security measures, the risks and uncertainties of the ability to attract new customers and retain and grow sales from existing customers; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology could make the products Twist Bioscience is developing obsolete or non-competitive; uncertainties of the retention of a significant customer; risks of third party claims alleging infringement of patents and proprietary rights or seeking to invalidate Twist Biosciences patents or proprietary rights; and the risk that Twist Biosciences proprietary rights may be insufficient to protect its technologies. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist Biosciences business in general, see Twist Biosciences risk factors set forth in Twist Biosciences Quarterly Report on Form 10-Q dated as of May 12, 2020. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200601005217/en/

View post:
Twist Bioscience to Join Proteona in Global Alliance to Protect Immunocompromised Patients From COVID-19 Infection - BioSpace

The subtle signs that point the way towards haemochromatosis – The Irish Times

By adminJune 2, 2020Gene Therapy Clinics

The first symptom I had was a hot flush. To say peri-menopausal was not on my radar is an understatement says Cathy Brooks, development manager with the UCD Foundation.

I had no idea. Id just lost my mum in October and I remember by Christmas being with friends in Collins Barracks, having a coffee walking around and I just started getting these hot flushes and I was thinking what the hell is this? To be honest, I just attributed it to the grief and losing my mum and all of that.

It was only when I googled it and I saw the symptoms that I thought, could I be? Im too young.

She was 39 at the time.

Initial blood tests suggested Cathy was not peri-menopausal but with her symptoms continuing she decided to seek advice from a second GP. On hearing her symptoms, the doctor immediately suspected haemochromatosis and decided to carry out a blood test.

I like to think Ive a very positive outlook on life, Cathy says, explaining how she made the decision that she wasnt going to focus on this. I just got on with living life.

Every year I go for a check-up in the haematology clinic in St Vincents . They do your bloods before and they check your liver, your heart all the organs that can be damaged. Its like going in for an annual MOT really, she continues.

Only in the last six months Ive started to get really achey in my index finger and my middle finger. When I close my fist I can feel my fingers kind of crunching. Thats a symptom of haemochromatosis.

Because Cathys joints are getting really stiff, she has been referred to a rheumatologist.

Cathy describes herself as being very active.

I do a lot of sport. I do it for my mental health as well as my physical health, she adds, discussing her love of rowing and cycling. But this year, like most of the world, Ive just been sitting on the couch eating, she says. Im more stiff now because Im not active.

Cathy has phlebotomies every three months to treat her haemochromatosis but shes keen that her blood doesnt go to waste just because of her condition.

If Ive to give blood for the rest of my life, I dont want my blood to be dumped because theres too much iron in it. I want my blood used. So I go to this clinic where they can use my blood, she says adding that people with haemochromatosis travel from all over the country to the clinic in Stillorgan for this very reason.

The service has been extended and now, many people with haemochromatosis can become regular blood donors at all blood donation clinics nationwide, including local community clinics.

Potential donors must meet specific haemochromatosis management criteria, the Irish Blood Transfusion Service states, which includes having completed iron depletion therapy, and not suffering from any serious complications as a result of haemochromatosis.

They must also satisfy standard blood donation criteria to be able to attend clinics to give blood which can then be used to save patients lives throughout the country

Thankfully, Cathy hasnt experienced any difficulties giving blood in Covid-19 times.

I happened to give blood about two weeks ago. Ive heard loads of people are having trouble giving blood during coronavirus. I havent had any problem. Ive had nothing but a positive experience with all of this and all the professionals.

What is haemochromatosis?

Haemochromatosis is a genetic condition which, in many people who have the condition, gives rise to excess iron absorption and retention within the body, explains Prof Suzanne Norris, professor of hepatology and gastroenterology, Trinity College, Dublin.

Over time, and its a very slow, gradual process, iron accumulation builds up and the iron is absorbed and deposited in various organs. We have the highest rate of haemochromatosis of any European and worldwide country

What are the symptoms of haemochromatosis?

Chronic fatigue is the main symptom, Prof Norris explains. Achey joints would be another. The problem with haemochromatosis is that it doesnt really have a symptom that would make you say aha thats haemochromatosis. Its all subtle signs. Its a disease thats under the radar because it doesnt produce a symptom that would make a doctor think that has to be that condition. Its literally chronic fatigue and unfortunately most chronic conditions will give rise to chronic fatigue.

How is haemochromatosis diagnosed?

To make the diagnosis, you need to have inherited the gene for excessive iron accumulation from both parents. Only about 50 per cent of people who have the two genes actually ever develop iron overload, so theres obviously another trigger, which may be environmental, we dont quite know, Professor Norris says.

What are the potential complications of haemochromatosis?

Typically the organs that end up having too much iron absorbed within them are the liver, the pancreas which may give rise to diabetes, the joints which may give rise to arthritis, Prof Norris explains.

Bronze diabetes, or brown discolouration of the skin is actually quite rare. There are other symptoms which may occur around depression and low mood. Its not clear whether thats just in relation to general inflammation because of the iron burden, or because of not feeling well and low mood associated with chronic ill health in that regard.

What is the treatment for haemochromatosis?

The treatment is very simple. Its blood letting or having blood removed on initially maybe a weekly or monthly basis in the acute stage when the person is coming in with a new diagnosis, ProfNorris explains.

Once the excess iron has been removed its like giving blood to the blood bank, you donate blood once or twice a year, that might be sufficient for most people. Some people may do it four times a year and that keeps the condition totally under control.

When the iron level is back within the normal range and its maintained at that level by either once to four times a year, depending on the persons needs, it keeps it completely under control and there is no risk of developing serious potential complications from late diagnosis once its diagnosed early, Professor Norris emphasises.

Our message is always, at this time of year, for healthcare professionals to really think about chronic fatigue could it be iron overload, rather than anaemia giving rise to chronic fatigue.

For more information, visit the Irish Haemochromatosis Association at haemochromatosis-ir.com (to donate 4, text IRON to 50300).

Originally posted here:
The subtle signs that point the way towards haemochromatosis - The Irish Times

Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size, Share, Growth, Trends and Forecast 2026 by Top Manufacturers,Segment Type s,…

By adminMay 29, 2020Gene Therapy Clinics

Latest Report On Juvenile Macular Degeneration (Stargardt Disease) Treatment Market includingMarket Landscape, and Market size, Revenues by players,Revenues by regions,Average prices,Competitive landscape, market Dynamics and industry trends and developments during the forecast period.

The global Juvenile Macular Degeneration (Stargardt Disease) Treatment market is broadly analyzed in this report that sheds light on critical aspects such as the vendor landscape, competitive strategies, market dynamics, and regional analysis. The report helps readers to clearly understand the current and future status of the global Juvenile Macular Degeneration (Stargardt Disease) Treatment market. The research study comes out as a compilation of useful guidelines for players to secure a position of strength in the global market. The authors of the report profile leading companies of the global Juvenile Macular Degeneration (Stargardt Disease) Treatment market, Also the details about important activities of leading players in the competitive landscape.

Some of the Leading Players in the Juvenile Macular Degeneration (Stargardt Disease) Treatment Market are: Sanofi, Bayer, Roche, Pfizer, Allergan, Gilead Sciences, Kubota Pharmaceutical, Alkeus Pharmaceuticals, Astellas Pharma, Ferrer Corporate, etc.

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1779850/covid-19-impact-on-juvenile-macular-degeneration-stargardt-disease-treatment-market

The report predicts the size of the global Juvenile Macular Degeneration (Stargardt Disease) Treatment market in terms of value and volume for the forecast period 2020-2026. As per the analysis provided in the report, the global Juvenile Macular Degeneration (Stargardt Disease) Treatment market is expected to rise at a CAGR of xx % between 2020 and 2026 to reach a valuation of US$ xx million/billion by the end of 2026. In 2020, the global Juvenile Macular Degeneration (Stargardt Disease) Treatment market attained a valuation of US$_ million/billion. The market researchers deeply analyze the global Juvenile Macular Degeneration (Stargardt Disease) Treatment industry landscape and the future prospects it is anticipated to create

This publication includes key segmentations of the global Juvenile Macular Degeneration (Stargardt Disease) Treatment market on the basis of product, application, and geography (country/region). Each segment included in the report is studied in relation to different factors such as consumption, market share, value, growth rate, and production.

The comparative results provided in the report allow readers to understand the difference between players and how they are competing against each other. The research study gives a detailed view of current and future trends and opportunities of the global Juvenile Macular Degeneration (Stargardt Disease) Treatment market. Market dynamics such as drivers and restraints are explained in the most detailed and easiest manner possible with the use of tables and graphs. Interested parties are expected to find important recommendations to improve their business in the global Juvenile Macular Degeneration (Stargardt Disease) Treatment market.

Segmental Analysis

The report has classified the global Juvenile Macular Degeneration (Stargardt Disease) Treatment industry into segments including product type and application. Every segment is evaluated based on growth rate and share. Besides, the analysts have studied the potential regions that may prove rewarding for the Juvenile Macular Degeneration (Stargardt Disease) Treatment manufcaturers in the coming years. The regional analysis includes reliable predictions on value and volume, thereby helping market players to gain deep insights into the overall Juvenile Macular Degeneration (Stargardt Disease) Treatment industry.

Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Segment By Type:

Stem Cell Therapy, Gene Therapy, Others Based

Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Segment By Application:

Hospitals, Eye Clinics, Others

Competitive Landscape

It is important for every market participant to be familiar with the competitive scenario in the global Juvenile Macular Degeneration (Stargardt Disease) Treatment industry. In order to fulfil the requirements, the industry analysts have evaluated the strategic activities of the competitors to help the key players strengthen their foothold in the market and increase their competitiveness.

Key companies operating in the global Juvenile Macular Degeneration (Stargardt Disease) Treatment market include: Sanofi, Bayer, Roche, Pfizer, Allergan, Gilead Sciences, Kubota Pharmaceutical, Alkeus Pharmaceuticals, Astellas Pharma, Ferrer Corporate, etc.

Enquire for customization in the report @https://www.qyresearch.com/customize-request/form/1779850/covid-19-impact-on-juvenile-macular-degeneration-stargardt-disease-treatment-market

Table of Contents

1.1 Research Scope1.2 Market Segmentation1.3 Research Objectives1.4 Research Methodology1.4.1 Research Process1.4.2 Data Triangulation1.4.3 Research Approach1.4.4 Base Year1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections1.5.2 Covid-19 Impact: Commodity Prices Indices1.5.3 Covid-19 Impact: Global Major Government Policy1.6 The Covid-19 Impact on Juvenile Macular Degeneration (Stargardt Disease) Treatment Industry1.7 COVID-19 Impact: Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Trends 2 Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Quarterly Market Size Analysis2.1 Juvenile Macular Degeneration (Stargardt Disease) Treatment Business Impact Assessment COVID-192.1.1 Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-20262.2 Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Quarterly Market Size 2020-20212.3 COVID-19-Driven Market Dynamics and Factor Analysis2.3.1 Drivers2.3.2 Restraints2.3.3 Opportunities2.3.4 Challenges 3 Quarterly Competitive Assessment, 20203.1 By Players, Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Quarterly Market Size, 2019 VS 20203.2 By Players, Juvenile Macular Degeneration (Stargardt Disease) Treatment Headquarters and Area Served3.3 Date of Key Players Enter into Juvenile Macular Degeneration (Stargardt Disease) Treatment Market3.4 Key Players Juvenile Macular Degeneration (Stargardt Disease) Treatment Product Offered3.5 Mergers & Acquisitions, Expansion Plans 4 Impact of Covid-19 on Juvenile Macular Degeneration (Stargardt Disease) Treatment Segments, By Type4.1 Introduction1.4.1 Stem Cell Therapy1.4.2 Gene Therapy1.4.3 Others4.2 By Type, Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size, 2019-2021 5 Impact of Covid-19 on Juvenile Macular Degeneration (Stargardt Disease) Treatment Segments, By Application5.1 Overview5.5.1 Hospitals5.5.2 Eye Clinics5.5.3 Others5.2 By Application, Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size, 2019-20215.2.1 By Application, Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Application, 2019-2021 6 Geographic Analysis6.1 Introduction6.2 North America6.2.1 Macroeconomic Indicators of US6.2.2 US6.2.3 Canada6.3 Europe6.3.1 Macroeconomic Indicators of Europe6.3.2 Germany6.3.3 France6.3.4 UK6.3.5 Italy6.4 Asia-Pacific6.4.1 Macroeconomic Indicators of Asia-Pacific6.4.2 China6.4.3 Japan6.4.4 South Korea6.4.5 India6.4.6 ASEAN6.5 Rest of World6.5.1 Latin America6.5.2 Middle East and Africa 7 Company Profiles7.1 Sanofi7.1.1 Sanofi Business Overview7.1.2 Sanofi Juvenile Macular Degeneration (Stargardt Disease) Treatment Quarterly Revenue, 20207.1.3 Sanofi Juvenile Macular Degeneration (Stargardt Disease) Treatment Product Introduction7.1.4 Sanofi Response to COVID-19 and Related Developments7.2 Bayer7.2.1 Bayer Business Overview7.2.2 Bayer Juvenile Macular Degeneration (Stargardt Disease) Treatment Quarterly Revenue, 20207.2.3 Bayer Juvenile Macular Degeneration (Stargardt Disease) Treatment Product Introduction7.2.4 Bayer Response to COVID-19 and Related Developments7.3 Roche7.3.1 Roche Business Overview7.3.2 Roche Juvenile Macular Degeneration (Stargardt Disease) Treatment Quarterly Revenue, 20207.3.3 Roche Juvenile Macular Degeneration (Stargardt Disease) Treatment Product Introduction7.3.4 Roche Response to COVID-19 and Related Developments7.4 Pfizer7.4.1 Pfizer Business Overview7.4.2 Pfizer Juvenile Macular Degeneration (Stargardt Disease) Treatment Quarterly Revenue, 20207.4.3 Pfizer Juvenile Macular Degeneration (Stargardt Disease) Treatment Product Introduction7.4.4 Pfizer Response to COVID-19 and Related Developments7.5 Allergan7.5.1 Allergan Business Overview7.5.2 Allergan Juvenile Macular Degeneration (Stargardt Disease) Treatment Quarterly Revenue, 20207.5.3 Allergan Juvenile Macular Degeneration (Stargardt Disease) Treatment Product Introduction7.5.4 Allergan Response to COVID-19 and Related Developments7.6 Gilead Sciences7.6.1 Gilead Sciences Business Overview7.6.2 Gilead Sciences Juvenile Macular Degeneration (Stargardt Disease) Treatment Quarterly Revenue, 20207.6.3 Gilead Sciences Juvenile Macular Degeneration (Stargardt Disease) Treatment Product Introduction7.6.4 Gilead Sciences Response to COVID-19 and Related Developments7.7 Kubota Pharmaceutical7.7.1 Kubota Pharmaceutical Business Overview7.7.2 Kubota Pharmaceutical Juvenile Macular Degeneration (Stargardt Disease) Treatment Quarterly Revenue, 20207.7.3 Kubota Pharmaceutical Juvenile Macular Degeneration (Stargardt Disease) Treatment Product Introduction7.7.4 Kubota Pharmaceutical Response to COVID-19 and Related Developments7.8 Alkeus Pharmaceuticals7.8.1 Alkeus Pharmaceuticals Business Overview7.8.2 Alkeus Pharmaceuticals Juvenile Macular Degeneration (Stargardt Disease) Treatment Quarterly Revenue, 20207.8.3 Alkeus Pharmaceuticals Juvenile Macular Degeneration (Stargardt Disease) Treatment Product Introduction7.8.4 Alkeus Pharmaceuticals Response to COVID-19 and Related Developments7.9 Astellas Pharma7.9.1 Astellas Pharma Business Overview7.9.2 Astellas Pharma Juvenile Macular Degeneration (Stargardt Disease) Treatment Quarterly Revenue, 20207.9.3 Astellas Pharma Juvenile Macular Degeneration (Stargardt Disease) Treatment Product Introduction7.9.4 Astellas Pharma Response to COVID-19 and Related Developments7.10 Ferrer Corporate7.10.1 Ferrer Corporate Business Overview7.10.2 Ferrer Corporate Juvenile Macular Degeneration (Stargardt Disease) Treatment Quarterly Revenue, 20207.10.3 Ferrer Corporate Juvenile Macular Degeneration (Stargardt Disease) Treatment Product Introduction7.10.4 Ferrer Corporate Response to COVID-19 and Related Developments 8 Key Findings 9 Appendix9.1 About US9.2 Disclaimer

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

View post:
Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size, Share, Growth, Trends and Forecast 2026 by Top Manufacturers,Segment Type s,...

Retinal Dystrophy Treatment Market Development, Market Trends, Key Driven Factors, Segmentation And Forecast To 2020-2026| GlaxoSmithKline, Applied…

By adminMay 24, 2020Gene Therapy Clinics

The research study presented here is an intelligent take on the global Retinal Dystrophy Treatment Market that explains important aspects such as competition, segmentation, and regional growth in great detail. Accuracy and preciseness are two of the key features of the report that reflect its authenticity. The authors of the report have focused on SWOT analysis, Porters Five Forces analysis, and PESTLE analysis of the global Retinal Dystrophy Treatment market. In addition, they have concentrated on qualitative and quantitative analyses to help with a deep understanding of the global Retinal Dystrophy Treatment market. Furthermore, the report provides powerful suggestions and recommendations to help players create strong growth strategies and ensure impressive sales in the global Retinal Dystrophy Treatment market.

Some of the influential Key Players operated in the report are: Spark Therapeutics (Roche), Novartis AG, GlaxoSmithKline, Applied Genetic Technologies Corporation, Oxford BioMedica, Biogen, HORAMA S.A., MeiraGTx Limited, Novelion Therapeutics, IVERIC bio, Reflection Biotechnologies Retinal Dystrophy Treatment Breakdown Data by Type, Gene Therapy Treatment, Symptomatic Treatment Retinal Dystrophy Treatment Breakdown Data by Application, Hospitals, Specialty Clinics, Others

To compile the detailed study of the global Retinal Dystrophy Treatment market, a robust research methodology has been adopted that aids in determining the key insights and also evaluates the growth prospects of the Retinal Dystrophy Treatment market. QY Research analysts have conducted in-depth primary and secondary research to obtain crucial insights into the Retinal Dystrophy Treatment market. To carry out secondary research, the analysts have collected the information through company annual reports, journals, company press releases, and paid databases that were referred to gain and identify better opportunities in the global market.

Get PDF Sample Copy of this Report including (Product, Summary, TOC, TOF, Industry analysis, Chart)

https://www.qyresearch.com/sample-form/form/1608847/global-retinal-dystrophy-treatment-market

As part of competitive analysis, the research study includes exhaustive company profiling of leading players of the global Retinal Dystrophy Treatment market. All of the segments studied in the report are analyzed based on different factors such as market share, revenue, and CAGR. The analysts have also thoroughly analyzed different regions such as North America, Europe, and the Asia Pacific on the basis of production, revenue, and sales in the global Retinal Dystrophy Treatment market. The researchers used advanced primary and secondary research methodologies and tools for preparing this report on the global Retinal Dystrophy Treatment market.

Segmentation by Type:

, Gene Therapy Treatment, Symptomatic Treatment Retinal Dystrophy Treatment

Segmentation by Application:

, Hospitals, Specialty Clinics, Others

Competitive Landscape

It is important for every market participant to be familiar with the competitive scenario in the global Retinal Dystrophy Treatment industry. In order to fulfil the requirements, the industry analysts have evaluated the strategic activities of the competitors to help the key players strengthen their foothold in the market and increase their competitiveness.

Key companies operating in the global Retinal Dystrophy Treatment market include Spark Therapeutics (Roche), Novartis AG, GlaxoSmithKline, Applied Genetic Technologies Corporation, Oxford BioMedica, Biogen, HORAMA S.A., MeiraGTx Limited, Novelion Therapeutics, IVERIC bio, Reflection Biotechnologies Retinal Dystrophy Treatment Breakdown Data by Type, Gene Therapy Treatment, Symptomatic Treatment Retinal Dystrophy Treatment Breakdown Data by Application, Hospitals, Specialty Clinics, Others

Table of Contents

1 Report Overview1.1 Study Scope1.2 Key Market Segments1.3 Players Covered: Ranking by Retinal Dystrophy Treatment Revenue1.4 Market Analysis by Type1.4.1 Global Retinal Dystrophy Treatment Market Size Growth Rate by Type: 2020 VS 20261.4.2 Gene Therapy Treatment1.4.3 Symptomatic Treatment1.5 Market by Application1.5.1 Global Retinal Dystrophy Treatment Market Share by Application: 2020 VS 20261.5.2 Hospitals1.5.3 Specialty Clinics1.5.4 Others1.6 Coronavirus Disease 2019 (Covid-19): Retinal Dystrophy Treatment Industry Impact1.6.1 How the Covid-19 is Affecting the Retinal Dystrophy Treatment Industry

1.6.1.1 Retinal Dystrophy Treatment Business Impact Assessment Covid-19

1.6.1.2 Supply Chain Challenges

1.6.1.3 COVID-19s Impact On Crude Oil and Refined Products1.6.2 Market Trends and Retinal Dystrophy Treatment Potential Opportunities in the COVID-19 Landscape1.6.3 Measures / Proposal against Covid-19

1.6.3.1 Government Measures to Combat Covid-19 Impact

1.6.3.2 Proposal for Retinal Dystrophy Treatment Players to Combat Covid-19 Impact1.7 Study Objectives1.8 Years Considered 2 Global Growth Trends by Regions2.1 Retinal Dystrophy Treatment Market Perspective (2015-2026)2.2 Retinal Dystrophy Treatment Growth Trends by Regions2.2.1 Retinal Dystrophy Treatment Market Size by Regions: 2015 VS 2020 VS 20262.2.2 Retinal Dystrophy Treatment Historic Market Share by Regions (2015-2020)2.2.3 Retinal Dystrophy Treatment Forecasted Market Size by Regions (2021-2026)2.3 Industry Trends and Growth Strategy2.3.1 Market Top Trends2.3.2 Market Drivers2.3.3 Market Challenges2.3.4 Porters Five Forces Analysis2.3.5 Retinal Dystrophy Treatment Market Growth Strategy2.3.6 Primary Interviews with Key Retinal Dystrophy Treatment Players (Opinion Leaders) 3 Competition Landscape by Key Players3.1 Global Top Retinal Dystrophy Treatment Players by Market Size3.1.1 Global Top Retinal Dystrophy Treatment Players by Revenue (2015-2020)3.1.2 Global Retinal Dystrophy Treatment Revenue Market Share by Players (2015-2020)3.1.3 Global Retinal Dystrophy Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.2 Global Retinal Dystrophy Treatment Market Concentration Ratio3.2.1 Global Retinal Dystrophy Treatment Market Concentration Ratio (CR5 and HHI)3.2.2 Global Top 10 and Top 5 Companies by Retinal Dystrophy Treatment Revenue in 20193.3 Retinal Dystrophy Treatment Key Players Head office and Area Served3.4 Key Players Retinal Dystrophy Treatment Product Solution and Service3.5 Date of Enter into Retinal Dystrophy Treatment Market3.6 Mergers & Acquisitions, Expansion Plans 4 Breakdown Data by Type (2015-2026)4.1 Global Retinal Dystrophy Treatment Historic Market Size by Type (2015-2020)4.2 Global Retinal Dystrophy Treatment Forecasted Market Size by Type (2021-2026) 5 Retinal Dystrophy Treatment Breakdown Data by Application (2015-2026)5.1 Global Retinal Dystrophy Treatment Market Size by Application (2015-2020)5.2 Global Retinal Dystrophy Treatment Forecasted Market Size by Application (2021-2026) 6 North America6.1 North America Retinal Dystrophy Treatment Market Size (2015-2020)6.2 Retinal Dystrophy Treatment Key Players in North America (2019-2020)6.3 North America Retinal Dystrophy Treatment Market Size by Type (2015-2020)6.4 North America Retinal Dystrophy Treatment Market Size by Application (2015-2020) 7 Europe7.1 Europe Retinal Dystrophy Treatment Market Size (2015-2020)7.2 Retinal Dystrophy Treatment Key Players in Europe (2019-2020)7.3 Europe Retinal Dystrophy Treatment Market Size by Type (2015-2020)7.4 Europe Retinal Dystrophy Treatment Market Size by Application (2015-2020) 8 China8.1 China Retinal Dystrophy Treatment Market Size (2015-2020)8.2 Retinal Dystrophy Treatment Key Players in China (2019-2020)8.3 China Retinal Dystrophy Treatment Market Size by Type (2015-2020)8.4 China Retinal Dystrophy Treatment Market Size by Application (2015-2020)(2015-2020) (2015-2020) 9 Key Players Profiles9.1 Spark Therapeutics (Roche)9.1.1 Spark Therapeutics (Roche) Company Details9.1.2 Spark Therapeutics (Roche) Business Overview and Its Total Revenue9.1.3 Spark Therapeutics (Roche) Retinal Dystrophy Treatment Introduction9.1.4 Spark Therapeutics (Roche) Revenue in Retinal Dystrophy Treatment Business (2015-2020))9.1.5 Spark Therapeutics (Roche) Recent Development9.2 Novartis AG9.2.1 Novartis AG Company Details9.2.2 Novartis AG Business Overview and Its Total Revenue9.2.3 Novartis AG Retinal Dystrophy Treatment Introduction9.2.4 Novartis AG Revenue in Retinal Dystrophy Treatment Business (2015-2020)9.2.5 Novartis AG Recent Development9.3 GlaxoSmithKline9.3.1 GlaxoSmithKline Company Details9.3.2 GlaxoSmithKline Business Overview and Its Total Revenue9.3.3 GlaxoSmithKline Retinal Dystrophy Treatment Introduction9.3.4 GlaxoSmithKline Revenue in Retinal Dystrophy Treatment Business (2015-2020)9.3.5 GlaxoSmithKline Recent Development9.4 Applied Genetic Technologies Corporation9.4.1 Applied Genetic Technologies Corporation Company Details9.4.2 Applied Genetic Technologies Corporation Business Overview and Its Total Revenue9.4.3 Applied Genetic Technologies Corporation Retinal Dystrophy Treatment Introduction9.4.4 Applied Genetic Technologies Corporation Revenue in Retinal Dystrophy Treatment Business (2015-2020)9.4.5 Applied Genetic Technologies Corporation Recent Development9.5 Oxford BioMedica9.5.1 Oxford BioMedica Company Details9.5.2 Oxford BioMedica Business Overview and Its Total Revenue9.5.3 Oxford BioMedica Retinal Dystrophy Treatment Introduction9.5.4 Oxford BioMedica Revenue in Retinal Dystrophy Treatment Business (2015-2020)9.5.5 Oxford BioMedica Recent Development9.6 Biogen9.6.1 Biogen Company Details9.6.2 Biogen Business Overview and Its Total Revenue9.6.3 Biogen Retinal Dystrophy Treatment Introduction9.6.4 Biogen Revenue in Retinal Dystrophy Treatment Business (2015-2020)9.6.5 Biogen Recent Development9.7 HORAMA S.A.9.7.1 HORAMA S.A. Company Details9.7.2 HORAMA S.A. Business Overview and Its Total Revenue9.7.3 HORAMA S.A. Retinal Dystrophy Treatment Introduction9.7.4 HORAMA S.A. Revenue in Retinal Dystrophy Treatment Business (2015-2020)9.7.5 HORAMA S.A. Recent Development9.8 MeiraGTx Limited9.8.1 MeiraGTx Limited Company Details9.8.2 MeiraGTx Limited Business Overview and Its Total Revenue9.8.3 MeiraGTx Limited Retinal Dystrophy Treatment Introduction9.8.4 MeiraGTx Limited Revenue in Retinal Dystrophy Treatment Business (2015-2020)9.8.5 MeiraGTx Limited Recent Development9.9 Novelion Therapeutics9.9.1 Novelion Therapeutics Company Details9.9.2 Novelion Therapeutics Business Overview and Its Total Revenue9.9.3 Novelion Therapeutics Retinal Dystrophy Treatment Introduction9.9.4 Novelion Therapeutics Revenue in Retinal Dystrophy Treatment Business (2015-2020)9.9.5 Novelion Therapeutics Recent Development9.10 IVERIC bio9.10.1 IVERIC bio Company Details9.10.2 IVERIC bio Business Overview and Its Total Revenue9.10.3 IVERIC bio Retinal Dystrophy Treatment Introduction9.10.4 IVERIC bio Revenue in Retinal Dystrophy Treatment Business (2015-2020)9.10.5 IVERIC bio Recent Development9.11 Reflection Biotechnologies10.11.1 Reflection Biotechnologies Company Details10.11.2 Reflection Biotechnologies Business Overview and Its Total Revenue10.11.3 Reflection Biotechnologies Retinal Dystrophy Treatment Introduction10.11.4 Reflection Biotechnologies Revenue in Retinal Dystrophy Treatment Business (2015-2020)10.11.5 Reflection Biotechnologies Recent Development 10 Analysts Viewpoints/Conclusions 11 Appendix11.1 Research Methodology11.1.1 Methodology/Research Approach11.1.2 Data Source11.2 Disclaimer11.3 Author Details

Enquire for customization in Report @

https://www.qyresearch.com/customize-request/form/1608847/global-retinal-dystrophy-treatment-market

Report Objectives

To carefully analyze and estimate the size of the global Retinal Dystrophy Treatment market. To clearly segment the global Retinal Dystrophy Treatment market and estimate the market size of the segments. To provide details about key strategies adopted by leading players of the global Retinal Dystrophy Treatment market. To help readers understand the current and future market scenarios. To provide information about the latest trends of the global Retinal Dystrophy Treatment market and its key segments. To assess the contribution of each region or country to the global Retinal Dystrophy Treatment market. To provide information on important drivers, restraints, and opportunities of the global Retinal Dystrophy Treatment market. To accurately calculate the market shares of key segments, regions, and companies in the global Retinal Dystrophy Treatment market.

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from the huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become a brand of quality assurance in the consulting industry.

See the original post here:
Retinal Dystrophy Treatment Market Development, Market Trends, Key Driven Factors, Segmentation And Forecast To 2020-2026| GlaxoSmithKline, Applied...

COVID-19 UPDATE: Precision Medicine Market 2020: Industry Analysis and Detailed Profiles of Top Industry Players are Neon Therapeutics, Moderna, Inc,…

By adminMay 24, 2020Gene Therapy Clinics

Global Precision Medicine Marketto grow with a substantial CAGR in the forecast period of 2019-2026. Growing prevalence of cancer worldwide and accelerating demand of novel therapies to prevent of cancer related disorders are the key factors for lucrative growth of market

Key Market Players:

Few of the major competitors currently working in the global precision medicine market are Neon Therapeutics, Moderna, Inc, Merck & Co., Inc, Bayer AG, PERSONALIS INC, GENOCEA BIOSCIENCES, INC., F. Hoffmann-La Roche Ltd, CureVac AG, CELLDEX THERAPEUTICS, BIONTECH SE, Advaxis, Inc, GlaxoSmithKline plc, Bioven International Sdn Bhd, Agenus Inc., Immatics Biotechnologies GmbH, Immunovative Therapies, Bristol-Myers Squibb Company, Gritstone Oncology, NantKwest, Inc among others.

Download Free PDF Sample Copy of[emailprotected]http://databridgemarketresearch.com/request-a-sample/?dbmr=global-precision-medicine-market

Global Precision Medicine MarketBy Application (Diagnostics, Therapeutics and Others), Technologies (Pharmacogenomics, Point-of-Care Testing, Stem Cell Therapy, Pharmacoproteomics and Others), Indication (Oncology, Central Nervous System (CNS) Disorders, Immunology Disorders, Respiratory Disorders, Others), Drugs (Alectinib, Osimertinib, Mepolizumab,Aripiprazole lauroxil and Others), Route of Administration (Oral,Injectable), End- Users (Hospitals, Homecare, Specialty Clinics, Others), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) Industry Trends and Forecast to 2026

Competitive Analysis:

The precision medicine market is highly fragmented and is based on new product launches and clinical results of products. Hence the major players have used various strategies such as new product launches, clinical trials, market initiatives, high expense on research and development, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of mass spectrometry market for global, Europe, North America, Asia Pacific and South America.

Market Drivers

Market Restraints

Talk to The Author of Report @http://databridgemarketresearch.com/speak-to-analyst/?dbmr=global-precision-medicine-market

Market Definition:

Precision medicines is also known as personalized medicines is an innovative approach to the patient care for disease treatment, diagnosis and prevention base on the persons individual genes. It allows doctors or physicians to select treatment option based on the patients genetic understanding of their disease.

According to the data published in PerMedCoalition, it was estimated that the USFDA has approved 25 novels personalized medicines in the year of 2018. These growing approvals annually by the regulatory authorities and rise in oncology and CNS disorders worldwide are the key factors for market growth.

Grab Your Report at an Impressive 30% Discount! Please click[emailprotected]https://www.databridgemarketresearch.com/request-a-discount/global-precision-medicine-market

Key Developments in the Market:

Competitive Analysis:

Global precision medicine market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of global precision medicine market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Market Segmentation:

By technology:-big data analytics, bioinformatics, gene sequencing, drug discovery, companion diagnostics, and others.

By application:- oncology, hematology, infectious diseases, cardiology, neurology, endocrinology, pulmonary diseases, ophthalmology, metabolic diseases, pharmagenomics, and others.

On the basis of end-users:- pharmaceuticals, biotechnology, diagnostic companies, laboratories, and healthcare it specialist.

On the basis of geography:- North America & South America, Europe, Asia-Pacific, and Middle East & Africa. U.S., Canada, Germany, France, U.K., Netherlands, Switzerland, Turkey, Russia, China, India, South Korea, Japan, Australia, Singapore, Saudi Arabia, South Africa, and Brazil among others.

In 2017, North America is expected to dominate the market.

About Data Bridge Market Research:

Data Bridge Market Researchset forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:[emailprotected]

Precision Cancer Therapies Market Set for Rapid Growth and Trends in 2020 to 2025 |Abbott Laboratories, Bayer HealthCare, GlaxoSmithKline, OncoGenex…

By adminMay 16, 2020Gene Therapy Clinics

Precision Cancer Therapies Market With COVID-19 Analysis 2020-2025:

The report has been prepared based on the synthesis, analysis, and interpretation of information about the Precision Cancer Therapies market collected from specialized sources. The competitive landscape section of the report provides a clear insight into the market share analysis of key industry players. company overview, financial overview, product portfolio, new project launched, recent development analysis are the parameters included in the profile.

Company overview, financial overview, product portfolio, new project launched, recent development analysis are the parameters included in the profile. The study then describes the drivers and restraints forthe marketalong with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the market on a global level.Finally, the report in order to meet the users requirements is also available.

Request a Sample PDF with COVID-19 Impact Analysis @https://garnerinsights.com/Global-Precision-Cancer-Therapies-Market-Report-History-and-Forecast-2014-2025-Breakdown-Data-by-Companies-Key-Regions-Types-and-Application#request-sample

The key manufacturers in this market include : Abbott Laboratories, Bayer HealthCare, GlaxoSmithKline, OncoGenex Pharmaceuticals, Hospira, Boehringer Ingelheim, AstraZeneca, Aveo Pharmaceuticals, .

By the product type, the market is primarily split into : Hormone Therapy, Immunotherapies, Targeted Therapy, Monoclonal Antibody Therapy, Gene Therapy,

By the end users/application, this report covers the following segments : Hospitals, Diagnostic Centers, Oncology Clinics, Research Institutes,

This study gives data on patterns and improvements, and spotlights on Markets and materials, limits and on the changing structure of the Precision Cancer Therapies Industry. The key motivation behind the report is to give a proper and key examination of this industry.

To get this report at a profitable rate: https://garnerinsights.com/Global-Precision-Cancer-Therapies-Market-Report-History-and-Forecast-2014-2025-Breakdown-Data-by-Companies-Key-Regions-Types-and-Application#discount

Reasons to invest in this report:

What does the report cover with respect to the regional landscape of the market?

Browse Full [emailprotected] https://garnerinsights.com/Global-Precision-Cancer-Therapies-Market-Report-History-and-Forecast-2014-2025-Breakdown-Data-by-Companies-Key-Regions-Types-and-Application

Moreover, the report includes analysis of different products available in the Precision Cancer Therapies market on the subject of production volume, revenue, pricing structure, and demand and supply figures.The report highlights profitable business strategies of market competitors along with their business expansion, composition, partnership deals, and new product/service launches.

Read the original:
Precision Cancer Therapies Market Set for Rapid Growth and Trends in 2020 to 2025 |Abbott Laboratories, Bayer HealthCare, GlaxoSmithKline, OncoGenex...

Why does immune response to coronavirus save some, kill others? – OCRegister

By adminMay 16, 2020Gene Therapy Clinics

Doctors in Southern California are working with researchers in Arizona to better understand the bodys sometimes bizarre immune response to COVID-19 an antibody onslaught that may kill the patient, rather than kill the virus.

The nonprofit Translational Genomics Research Institute (TGen), an affiliate of City of Hope, is peering into specific proteins on the virus to see how they react with different antibodies a high-resolution view that might guide treatment, testing and vaccine development.

The hypothesis is that antibodies can make things worse, and thats whats killing some people, said John Altin, assistant professor in TGens infectious-disease branch. We want to understand how that might be different from an immune response that protects somebody.

As many critically ill patients are treated in clinical trials with convalescent plasma therapy that is, injecting antibodies from recovered COVID-19 patients into those who are very ill, in hopes of triggering protective immune responses its imperative to understand whats behind the differing reactions.

Usually, antibodies provide protection, but there may be a bit of an exception with this virus, Altin said. That is a serious concern.

To that end, TGen and the Center for Gene Therapy at City of Hope are cooperating on a COVID Immunity Study that aims to collect blood from COVID-19 survivors.

The researchers will analyze your blood and profile your immune memory, the study consent form explains.

Participants can use the TGen kit at home. Theyll get a study kit by mail and collect one small spot blood sample, via a finger-prick device, for two consecutive weeks. Then theyll mail the study kit back to TGen.

About 500 people are expected to participate through the course of the study, and researchers may reach out for additional samples, and/or with additional questions, to see how immune memory changes over time.

Participants must be U.S. residents, at least 18 years old, have tested positive for COVID-19, and then recovered. For more information, see https://covidimmunity.org/.

This will help us learn more about how, when and why we produce antibodies in response to a COVID-19 infection, said David Engelthaler, director of TGen North, in a prepared statement. One class of antibodies tackles the infection first, and then another comes in to finish the job. Knowing when these different immune responses occur, and how long they last, could help us understand if some patients gain a certain degree of immunity against reinfection. We need to know how that works.

While large-scale clinical trials involving convalescent plasma are under way all over the nation, this study aims not to treat the disease, but to better understand the mechanisms behind it.

TGen describes its approach as a high-resolution view of the antibody response. It seeks to not only map the viruss proteins in detail, but to also see which parts of those proteins are targeted by antibodies.

Our approach will not only tell you which proteins arebeing targeted, but also be able to tell which regions of each protein are being targeted, Altin said in a statement. Each protein can be recognized by many different types of antibodies. By looking at this level of detail, we then could see elements of the antibody response that others might be missing.

TGen hopes to tease out subtle differences that can help develop therapies, vaccines and better antibody testing.

Others are looking at responses to the entire protein. Our approach is a little different. When we look at the antibody response, we divide it up into thousands of pieces. Theres potential for that to tell us what a beneficial and un-beneficial response might look like, Altin said.

John Zaia, director of the Center for Gene Therapy at City of Hope, is working with TGen, and has other COVID-19-related projects happening as well.

Zaia is leading a research project at City of Hope, in collaboration with Altins lab, that could lead to development of a COVID-19 virus antibody neutralization test, which would quantify antibodies.

Zaia also has received a $750,000 grant from the California Institute for Regenerative Medicine for a clinical study on the use of blood plasma as a potential treatment for COVID-19.

Theyre doing what you could call qualitative and quantitative measurements of the nature of the antibody what does it actually bind to? Zaia said. The virus has this surface protein, the spike protein, but there are also other things the immune system might be seeing. It might be focused on one or more parts of the spike.

The CIRM project will focus on finding plasma donors to determine if theres any correlation between the outcome in the sick patient who received the plasma and the specific antibody that went in. It will focus on under-served areas.

Duarte-based City of Hope was founded in 1913 and is a founding member of the National Comprehensive Cancer Network. It has many sites throughout Southern California, and is investing $1 billion to establish clinics and a cancer center in Orange County. A clinic opened in Newport Beach in January, and a hospital dedicated to cancer treatment and research is slated for Irvine.

On the forefront of science, new discoveries are made every day and so much is still unknown.

I think the FDA said it best: Theres no way that one group could solve all the problems, do all the testing that needs to be done, Zaia said. The whole field is so new.

Theres a balance that must be struck between moving quickly and moving carefully, Altin said. We should know a lot in the next three months about how the antibody response looks, he said. Vaccine development will take much longer.

Link:
Why does immune response to coronavirus save some, kill others? - OCRegister

Global Choroideremia Treatment Market Growth, Outlook, Trend and Forecast by Wize Pharma Inc, Spark Therapeutics, Inc, PIXIUM VISION, Retina Implant…

By adminMay 14, 2020Gene Therapy Clinics

Market Definition:

Choroideremia is also known as choroidal sclerosis is a rare, degenerative, X-linked inherited retinal disorder characterized by progressive degeneration of the choroid, retinal pigment epithelium (RPE) and retina due to Mutations in the CHM gene. This CHM gene required to produce Rab escort protein-1 (REP-1). The condition gets its name from the distinctive sweet odor of affected infants urine and is also c, a protein that takes part in targeting vesicles (small sacs of substances) into, out of, and within cells.

According to the statistics published by U.S. Department of Health & Human Services, an estimated population of choroideremia is about 1 in 50,000-100,000 people. Presence of refined healthcare infrastructure and emerging new market are the key factors for growth of this market.

Global Choroideremia Treatment Market By Treatment Type (Gene Therapy, Surgery), Route of Administration (Oral, Injectable), End- Users (Hospitals, Homecare, Specialty Clinics, Ophthalmic Clinics and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) Forecast to 2026

Global Choroideremia Treatment Marketis expected to grow at a steady CAGR in the forecast period of 2019-2026.Increase in strategic alliances between the pharmaceuticals companies and high demand of disease specific novel therapies are the key factors that fueling the market growth.

Some of the major competitors currently working in the global choroideremia treatment market areBiogen, 4D Molecular Therapeutics, Copernicus Therapeutics, Inc, Wize Pharma Inc, Spark Therapeutics, Inc, PIXIUM VISION, Retina Implant AG, F. Hoffmann-La Roche Ltd and others.

Download exclusive PDF sample report @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-choroideremia-treatment-market

Market Drivers

Market Restraints

Segmentation:Global Choroideremia Treatment Market

By Treatment

By Route of Administration

By End Users

By Distribution Channel

ByGeography

Download Detailed TOC @https://www.databridgemarketresearch.com/toc/?dbmr=global-choroideremia-treatment-market

Key Developments in the Market:

Competitive Analysis:

Global choroideremia treatment market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares global choroideremia treatment market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Reasons to Purchase this Report

Order a Copy of Global Choroideremia Treatment Market Report @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-choroideremia-treatment-market

About Data Bridge Market Research

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:Corporatesales@databridgemarketresearch.com

The rest is here:
Global Choroideremia Treatment Market Growth, Outlook, Trend and Forecast by Wize Pharma Inc, Spark Therapeutics, Inc, PIXIUM VISION, Retina Implant...

Why does immune response to coronavirus save some, kill others? – East Bay Times